Half-year report · HY
8086.TEDINET S100X3LO
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥317.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥644.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥312.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥15.3bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥13.5bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥8.2bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥10.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.5bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥12.4bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.1bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥129m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥6.6bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥813m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥1.15T | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥1.17T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.17T | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥855.9bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥858.9bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥297.7bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥311.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥298.1bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥110.0bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥106.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥104.9bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥101.7bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥85.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥96.6bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥16.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥68.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥15.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥13.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥71.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥54.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥5.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥23.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥36.21 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.36 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥0.79 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥32.08 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥27.78 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥0.7 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 20.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥3.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥499m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥431m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥40.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥40.3bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥13.1bn |
| Medical Treatment Relatedreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥256.3bn |
| Medical Treatment Relatedreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥252.6bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3.8bn |
| Medical Treatment Relatedreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥23.9bn |
| Medicine Relatedreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥66.7bn |
| Medicine Relatedreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥37.1bn |
| Medicine Relatedreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥29.6bn |
| Medicine Relatedreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.9bn |
| Pharma Packagingreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥31.2bn |
| Pharma Packagingreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥27.2bn |
| Pharma Packagingreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4.0bn |
| Pharma Packagingreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥861m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥354.2bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥316.9bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥37.3bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥28.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥357.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥317.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥40.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥28.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥383m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥272m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥39.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥39.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥14.9bn |
| Medical Treatment Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥245.6bn |
| Medical Treatment Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥242.1bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| Medical Treatment Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥24.5bn |
| Medicine Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥68.4bn |
| Medicine Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥38.0bn |
| Medicine Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥30.4bn |
| Medicine Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.2bn |
| Pharma Packagingreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥34.9bn |
| Pharma Packagingreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥31.6bn |
| Pharma Packagingreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3.3bn |
| Pharma Packagingreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥931m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥348.9bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥311.6bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥37.3bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥28.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥351.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥312.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥39.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥28.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 645
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02688-000MedicineRelatedReportableSegmentsMember | 37089000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02688-000PharmaPackagingReportableSegmentMember | 27224000000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 316882000000 | JPY |
| Revenues from external customers | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 499000000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 317382000000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 317382000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 3753000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E02688-000MedicineRelatedReportableSegmentsMember | 29585000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E02688-000PharmaPackagingReportableSegmentMember | 3979000000 | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | 37317000000 | JPY |
| Transactions with other segments | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2983000000 | JPY |
| Transactions with other segments | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 40301000000 | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | -40301000000 | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 256321000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E02688-000MedicineRelatedReportableSegmentsMember | 66675000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E02688-000PharmaPackagingReportableSegmentMember | 31203000000 | JPY |
| Net sales | InterimDuration_ReportableSegmentsMember | 354200000000 | JPY |
| Net sales | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3482000000 | JPY |
| Net sales | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 357683000000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | -40301000000 | JPY |
| Net sales | InterimDuration | 317382000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 23949000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E02688-000MedicineRelatedReportableSegmentsMember | 4914000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E02688-000PharmaPackagingReportableSegmentMember | -861000000 | JPY |
| Operating income | InterimDuration_ReportableSegmentsMember | 28002000000 | JPY |
| Operating income | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 431000000 | JPY |
| Operating income | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 28434000000 | JPY |
| Operating income | InterimDuration_ReconcilingItemsMember | -13097000000 | JPY |
| Operating income | InterimDuration | 15337000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-14 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第73期中(自 2025年４月１日 至 2025年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ニプロ株式会社 | |
| Company name in english cover page | FilingDateInstant | NIPRO CORPORATION | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 山 崎 剛 司 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)大阪府摂津市千里丘新町３番26号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 06(6310)6804 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)専務取締役 最高財務責任者 余 語 岳 仁 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)大阪府摂津市千里丘新町３番26号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 06(6310)6804 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)専務取締役 最高財務責任者 余 語 岳 仁 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E02688 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 80860 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ニプロ株式会社 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |